Clinical Trials Logo

Chronic Hepatitis C clinical trials

View clinical trials related to Chronic Hepatitis C.

Filter by:

NCT ID: NCT03693586 Recruiting - Chronic Hepatitis c Clinical Trials

Study to Determine the Hepatitis C Virus Infection Prevalence Among Patients Attended Primarily for Vasculitis

Start date: September 19, 2018
Phase:
Study type: Observational

Although it is classically considered that chronic hepatitis C infection (CHC) is usually asymptomatic, there are studies that show that up to two thirds of patients may present some type of extrahepatic manifestation. The most frequent extrahepatic manifestation is type II mixed cryoglobulinemia (MCG-II) and clinically the most common presentation is leukocytoclastic vasculitis (LCV) with palpable purpura that affects the lower extremities. It is estimated that up to 80% of MCG-II cases are due to CHC. Previous studies have demonstrated that CHC prevalence is higher in patients with autoinmune diseases compared with general popullation. Therefore, we hypothesize that If vasculitis is an extrahepatic manifestation of CHC, then the prevalence of CHC infection in this group of patients will be higher than that reported in the general population. Our aim is to know the prevalence of CHC, determined by serological rapid test for hepatitis C screening and all positive cases will be confirmed by quantitative viral load, in patients who consult primarily to a rheumatology department for "vasculitis" or other potential extrahepatic manifestations (rheumatological conditions).

NCT ID: NCT03687229 Not yet recruiting - Chronic Hepatitis c Clinical Trials

The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients

Start date: January 2019
Phase:
Study type: Observational [Patient Registry]

The hepatitis C virus is a major cause of chronic liver diseases, including cirrhosis and hepatocellular carcinoma, and infects approximately 3 % of the world population (150-170 million). It is estimated that approximately 80 % of patients with acute hepatitis C fail to eliminate the virus and become chronically infected Hepatitis C virus infection is strongly associated with the dysregulation of glucose homoeostasis such as insulin resistance and type 2 diabetes. Despite these findings of insulin resistance development via direct effects on insulin signalling pathway, the complex relationship between intrahepatic Hepatitis C virus infection and extrahepatic insulin resistance remains elusive. One of the countries most affected by Hepatitis C virus is Egypt. The Egyptian Demographic and Health Surveys measured antibody prevalence among the adult population aged 15-59 years at 10.0% in 2015—substantially higher than global levels. Several micro ribonucleic acids have been determined to play a key role in regulating viral replication and pathogenesis during infection. micro ribonucleic acid-122 expression is enriched in the liver, accounting for approximately 70 % of the total micro ribonucleic acid population in normal adult hepatocytes. Moreover, a particularly intriguing function of micro ribonucleic acid-122 involves its role in the Hepatitis C virus replication cycle. Antagonism of micro ribonucleic acid-122 not only reduces viral replication but also reduces Hepatitis C virus propagation by decreasing the expression of enzymes involved in lipid metabolism, which can enhance Hepatitis C virus replication in cell culture models.

NCT ID: NCT03673696 Recruiting - Chronic Hepatitis c Clinical Trials

The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects

Start date: September 4, 2018
Phase: Phase 1
Study type: Interventional

The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects

NCT ID: NCT03612973 Not yet recruiting - Chronic Hepatitis c Clinical Trials

Changes in Liver Fibrosis, Lipid Profile and Insulin Resistance in HCV Patients Who Received Antiviral Therapy

Start date: December 1, 2018
Phase: N/A
Study type: Interventional

Hepatitis C virus (HCV) is one of the major globally cause of death and morbidity.Chronic hepatitis C is the leading cause of end-stage liver disease, hepatocellular carcinoma and liver-related death in Egypt.It could be considered a special type of metabolic diseases involving insulin resistance (IR) which accelerates fibrosis and modulation of lipid-cholesterol biosynthesis with increased risk for ischemic heart diseases.It could be considered a special type of metabolic diseases involving insulin resistance (IR) which accelerates fibrosis and modulation of lipid-cholesterol biosynthesis with increased risk for ischemic heart diseases .Increased prevalence of IR and type 2 diabetes mellitus extensively reported in HCV infections

NCT ID: NCT03510637 Recruiting - Chronic Hepatitis C Clinical Trials

"Real Life" Evaluation of Efficacy and Safety of Direct Antiviral Agents (DAAs) for the Treatment of Hepatitis C Virus in Egypt

HepNile
Start date: January 22, 2018
Phase:
Study type: Observational

The primary purpose of the ANRS 12332 HepNile study cohort is to assess in "Real-Life" condition the efficacy and the safety profile of new Direct Acting Antivirals (DAAs) introduced in the Egyptian National Treatment Programme for the treatment of Chronic Hepatitis C (CHC).

NCT ID: NCT03501550 Active, not recruiting - Chronic Hepatitis C Clinical Trials

Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)

Start date: June 26, 2018
Phase: Phase 2
Study type: Interventional

Open label phase 2a study of two week treatment with CDI-31244 and sofosbuvir and veltapasvir followed by four week treatment of sofosbuvir and velpatasvir in individuals with chronic hepatitis C (HCV) genotype 1 (GT1) infection

NCT ID: NCT03500562 Recruiting - Chronic Hepatitis C Clinical Trials

Study of Daclatasvir-based Therapy in Chinese Participants With Chronic Hepatitis C (CHC)

Start date: April 17, 2018
Phase:
Study type: Observational

Study is a non-interventional, prospective, multicenter post marketing surveillance study to determine the safety of daclatasvir based therapy

NCT ID: NCT03495570 Not yet recruiting - Chronic Hepatitis C Clinical Trials

Sysmex-XN 20 Analyser to Assess Lymphocyte Subsets and Other Haematological Parameters in Chronic/Acute Viral Infections

SASA
Start date: April 15, 2018
Phase:
Study type: Observational

The XN-20, is a full blood count (FBC) analyser with an extended differential counting and flagging System. The XN-Series' individual channels allow real-time reflex analysis, and uses a two stage process to classify the white blood count (WBC) sub-populations and detect the presence of abnormal reactive and malignant cells. In regards to lymphocytes in the peripheral blood, the machine has the capacity to distinguish activated from non-activated T-cell subsets using a very small volume of EDTA sample (88uL) (including remnant sample from a standard full blood count) with results available in 1.5 minutes. It is a fully automated process and can be considered as an alternative rapid flow cytometry method. Objective of the SASA study: to investigate the signal pattern of white blood cells assessed using the XN-20 full blood count platform in patients with untreated viral infections i.e. HIV, HCV and HBV. The data from the analysis will be reviewed in conjunction with patient's demographic and clinical disease characteristics with the aim of detecting characteristic cell populations that can be used in the development of system flags for future studies.

NCT ID: NCT03490097 Completed - Metabolic Syndrome Clinical Trials

Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination

Start date: December 1, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of the study is to determine if statin can affect the clinical outcome of chronic hepatitis C patients receiving Sofosbuvir/Daclatasvir/Ribavirin combination

NCT ID: NCT03488485 Recruiting - Chronic Hepatitis c Clinical Trials

Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model

Start date: June 18, 2016
Phase: N/A
Study type: Interventional

Background and Aims: The prevalence of hepatitis C virus infection (HCV) infection in Punjab, India is 3.29%, with an estimated burden of around 650,000 viremic chronic HCV (CHC) patients. The Mukh Mantri Punjab Hepatitis C Relief Fund (MMPHCRF) was launched in June 2016 to provide free treatment to all CHC aiming to eliminate HCV from Punjab. The study assessed the feasibility of decentralized care and efficacy and safety of 12 or 24 weeks of sofosbuvir (SOF) + ledipasvir (LDV) or SOF + daclatasvir (DCV) ± ribavirin (RBV) in the treatment of CHC patients in a public health care setting.